Melissa McCracken, Ph.D., joined Nextech Invest Ltd. in 2019. Melissa is a scientist by training with a passion for emerging technologies in cancer therapies. Melissa is a board observer of IconOvir, and a previous board member of ImaginAb and board observer of Silverback Therapeutics.
Prior to Nextech, Melissa was a senior associate at Third Rock Ventures focusing on scientific due diligence, partnership development and new company formation in oncology and immunology. Melissa helped build and launch Celsius Therapeutics, a company focused on discovering precision therapeutics for oncology and autoimmune. Melissa has also worked within larger biotech organizations completing multiple internships in research and development at Amgen (NASDAQ: AMGN).
Melissa holds a B.S. in biochemistry and molecular biology from University of California, Davis, a Ph.D. in molecular and medical pharmacology from University of California, Los Angeles with her research focused on engineered immunity for cancer. Melissa also completed a postdoctoral fellowship at Stanford University where her research focused on immuno-oncology.
Melissa is attending / has attended:
Venture Summit Virtual Connect 3